Cancer Immunotherapy and Biomarkers
This cluster of papers focuses on the advances in cancer immunotherapy research, particularly in the context of immune checkpoint blockade targeting PD-1 and PD-L1, the impact of tumor microenvironment, biomarkers for immunotherapy response, T-cell exhaustion, neoantigens, tumor mutational burden, immune-related adverse events, and the exploration of combination therapies. The research also delves into the intricate mechanisms of cancer immunoediting.
Papers listed on taxonomy pages are the top few works per node from the OpenAlex snapshot. That list is not exhaustive and is not an endorsement. The topic map and the journal registry remain separate: there is still no authoritative topic-to-venue or topic-to-organization edge. Search is a lexical lookup, not a claim that a venue publishes a topic.
Most cited
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- The blockade of immune checkpoints in cancer immunotherapy
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Immunity, Inflammation, and Cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Most recent
- Tumor-directed 4-1BB agonism with dual checkpoint blockades drives CD8 T cell remodeling and Treg fragility in immune cold tumors
- Safety of immune checkpoint inhibitor rechallenge and mid-term outcomes after suspected cardiovascular immune-related adverse events
- Quinine modulates PD-L1 and STAT3 in MCF-7 cells: An in silico and in vitro study
- HLA class I expression and tumor immune infiltration together shape colon cancer immune contexture
- A phase II multi-institutional single arm trial evaluating TG4010 vaccine plus nivolumab in non-small cell lung cancer
- A reproducible pipeline for TCR β-chain repertoire analysis from thoracic tumour RNA-seq and ICI-associated cardiac immunotoxicity